Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients.
Gentler drug combinations offer hope for older or frail lymphoma patients who cannot tolerate standard harsh chemotherapy regimens.
Older or medically unfit patients with diffuse large B-cell lymphoma (DLBCL) frequently cannot tolerate standard anthracycline-based immunochemotherapy, creating a persistent unmet clinical need. Trial registration: #NCT03677154.
What the study was
- Study design
- Review
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Blood
Why it surfaced
Score 7/10; Design: Review; Topics: Hematologic malignancies
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.